A deep-dive reference for pharma/biotech IP teams, R&D leads, portfolio managers, and institutional investors who need forecasts that hold up […]
A deep-dive reference for pharma IP counsel, portfolio managers, R&D leads, and institutional investors who need to turn litigation data
Key Takeaways (Executive Summary) Part 1: The Compounding Regulatory Architecture The Market Context The U.S. compounding pharmacy sector is not
Key Takeaways (Executive Summary) Part I: The R&D Productivity Crisis and the AI Imperative The Economics Are Broken The math
Patent Data Is the Missing Ingredient Powering AI Drug Discovery Read Post »
How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space
The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production
Drug Patent Data Is Your Supply Chain’s Most Accurate Forecasting Tool Read Post »
Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is
NDC Composition Data: The Excipient R&D Roadmap That Cuts Guesswork Read Post »
Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the
Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration.
Sign in or create a free account to read this DrugPatentWatch article
